Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report
With the advent of immunotherapies, the field of cancer therapy has been revived with new hope, especially for cancers with dismal prognoses, such as the glioblastoma multiforme (GBM). Currently, immunotherapies should potentiate the host’s own antitumor immune response against cancer cells, but it...
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-01-01
|
| Series: | Biomedicines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2227-9059/11/2/311 |
| _version_ | 1797622213826838528 |
|---|---|
| author | Navid Sobhani Victoria Bouchè Giovanni Aldegheri Andrea Rocca Alberto D’Angelo Fabiola Giudici Cristina Bottin Carmine Antonio Donofrio Maurizio Pinamonti Benvenuto Ferrari Stefano Panni Marika Cominetti Jahard Aliaga Marco Ungari Antonio Fioravanti Fabrizio Zanconati Daniele Generali |
| author_facet | Navid Sobhani Victoria Bouchè Giovanni Aldegheri Andrea Rocca Alberto D’Angelo Fabiola Giudici Cristina Bottin Carmine Antonio Donofrio Maurizio Pinamonti Benvenuto Ferrari Stefano Panni Marika Cominetti Jahard Aliaga Marco Ungari Antonio Fioravanti Fabrizio Zanconati Daniele Generali |
| author_sort | Navid Sobhani |
| collection | DOAJ |
| description | With the advent of immunotherapies, the field of cancer therapy has been revived with new hope, especially for cancers with dismal prognoses, such as the glioblastoma multiforme (GBM). Currently, immunotherapies should potentiate the host’s own antitumor immune response against cancer cells, but it has been documented that they are effective only in small subsets of patients. Therefore, accurate predictors of response are urgently needed to identify who will benefit from immune-modulatory therapies. Brain tumors are challenging in terms of treatments. The immune response in the brain is highly regulated, and the immune microenvironment in brain metastases is active with a high density of tumor-infiltrating lymphocytes (TILs, CD3+ T cells) in certain patients and, therefore, may serve as a potential treatment target. In our study, we performed immunohistochemistry for CD3 and PD-L1 along the routine assessment of the O6-methylguanine-methyltransferase (MGMT) promoter methylation status and the IDH1 and 2 status in a single center cohort of 69 patients with GBM (58 primary tumors and 11 recurrences) who underwent standard multimodal therapies (surgery/radiotherapy/adjuvant temozolamide). We analyzed the association of PD-L1 tumor expression and TILs with overall survival (OS). The PD-L1 expression was observed in 25 of 58 (43%) newly diagnosed primary glioblastoma specimens. The sparse-to-moderate density of TILs, identified with CD3+ expression, was found in 48 of 58 (83%) specimens. Neither PD-L1 expression nor TILs were associated with overall survival. In conclusion, TILs and/or PD-L1 expression are detectable in the majority of glioblastoma samples, and even if they slightly relate to the outcome, they do not show a statistically significant correlation. |
| first_indexed | 2024-03-11T09:06:59Z |
| format | Article |
| id | doaj.art-765c12e4ebaf47da9beb45e9574bf7a1 |
| institution | Directory Open Access Journal |
| issn | 2227-9059 |
| language | English |
| last_indexed | 2024-03-11T09:06:59Z |
| publishDate | 2023-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomedicines |
| spelling | doaj.art-765c12e4ebaf47da9beb45e9574bf7a12023-11-16T19:16:19ZengMDPI AGBiomedicines2227-90592023-01-0111231110.3390/biomedicines11020311Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center ReportNavid Sobhani0Victoria Bouchè1Giovanni Aldegheri2Andrea Rocca3Alberto D’Angelo4Fabiola Giudici5Cristina Bottin6Carmine Antonio Donofrio7Maurizio Pinamonti8Benvenuto Ferrari9Stefano Panni10Marika Cominetti11Jahard Aliaga12Marco Ungari13Antonio Fioravanti14Fabrizio Zanconati15Daniele Generali16Department of Medicine, Section of Epidemiology and Population Sciences, Baylor College of Medicine, Houston, TX 77030, USADepartment of Medical, Surgery and Health Sciences, University of Trieste, 34147 Trieste, ItalyDepartment of Medical, Surgery and Health Sciences, University of Trieste, 34147 Trieste, ItalyDepartment of Medical, Surgery and Health Sciences, University of Trieste, 34147 Trieste, ItalyDepartment of Biology & Biochemistry, University of Bath, Bath BA27AY, UKDepartment of Medical, Surgery and Health Sciences, University of Trieste, 34147 Trieste, ItalyDepartment of Medical, Surgery and Health Sciences, University of Trieste, 34147 Trieste, ItalyNeurosurgery, ASST Cremona, Viale Concordia 1, 26100 Cremona, ItalyDepartment of Medical, Surgery and Health Sciences, University of Trieste, 34147 Trieste, ItalyBreast and Brain Unit, ASST Cremona, Viale Concordia 1, 26100 Cremona, ItalyBreast and Brain Unit, ASST Cremona, Viale Concordia 1, 26100 Cremona, ItalyNeurosurgery, ASST Cremona, Viale Concordia 1, 26100 Cremona, ItalyNeurosurgery, ASST Cremona, Viale Concordia 1, 26100 Cremona, ItalyPathology Unit, ASST Cremona, Viale Concordia 1, 26100 Cremona, ItalyNeurosurgery, ASST Cremona, Viale Concordia 1, 26100 Cremona, ItalyDepartment of Medical, Surgery and Health Sciences, University of Trieste, 34147 Trieste, ItalyDepartment of Medical, Surgery and Health Sciences, University of Trieste, 34147 Trieste, ItalyWith the advent of immunotherapies, the field of cancer therapy has been revived with new hope, especially for cancers with dismal prognoses, such as the glioblastoma multiforme (GBM). Currently, immunotherapies should potentiate the host’s own antitumor immune response against cancer cells, but it has been documented that they are effective only in small subsets of patients. Therefore, accurate predictors of response are urgently needed to identify who will benefit from immune-modulatory therapies. Brain tumors are challenging in terms of treatments. The immune response in the brain is highly regulated, and the immune microenvironment in brain metastases is active with a high density of tumor-infiltrating lymphocytes (TILs, CD3+ T cells) in certain patients and, therefore, may serve as a potential treatment target. In our study, we performed immunohistochemistry for CD3 and PD-L1 along the routine assessment of the O6-methylguanine-methyltransferase (MGMT) promoter methylation status and the IDH1 and 2 status in a single center cohort of 69 patients with GBM (58 primary tumors and 11 recurrences) who underwent standard multimodal therapies (surgery/radiotherapy/adjuvant temozolamide). We analyzed the association of PD-L1 tumor expression and TILs with overall survival (OS). The PD-L1 expression was observed in 25 of 58 (43%) newly diagnosed primary glioblastoma specimens. The sparse-to-moderate density of TILs, identified with CD3+ expression, was found in 48 of 58 (83%) specimens. Neither PD-L1 expression nor TILs were associated with overall survival. In conclusion, TILs and/or PD-L1 expression are detectable in the majority of glioblastoma samples, and even if they slightly relate to the outcome, they do not show a statistically significant correlation.https://www.mdpi.com/2227-9059/11/2/311PD-L1CD3biomarkersimmune checkpoint inhibitorsglioblastoma |
| spellingShingle | Navid Sobhani Victoria Bouchè Giovanni Aldegheri Andrea Rocca Alberto D’Angelo Fabiola Giudici Cristina Bottin Carmine Antonio Donofrio Maurizio Pinamonti Benvenuto Ferrari Stefano Panni Marika Cominetti Jahard Aliaga Marco Ungari Antonio Fioravanti Fabrizio Zanconati Daniele Generali Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report Biomedicines PD-L1 CD3 biomarkers immune checkpoint inhibitors glioblastoma |
| title | Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report |
| title_full | Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report |
| title_fullStr | Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report |
| title_full_unstemmed | Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report |
| title_short | Analysis of PD-L1 and CD3 Expression in Glioblastoma Patients and Correlation with Outcome: A Single Center Report |
| title_sort | analysis of pd l1 and cd3 expression in glioblastoma patients and correlation with outcome a single center report |
| topic | PD-L1 CD3 biomarkers immune checkpoint inhibitors glioblastoma |
| url | https://www.mdpi.com/2227-9059/11/2/311 |
| work_keys_str_mv | AT navidsobhani analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT victoriabouche analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT giovannialdegheri analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT andrearocca analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT albertodangelo analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT fabiolagiudici analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT cristinabottin analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT carmineantoniodonofrio analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT mauriziopinamonti analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT benvenutoferrari analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT stefanopanni analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT marikacominetti analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT jahardaliaga analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT marcoungari analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT antoniofioravanti analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT fabriziozanconati analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport AT danielegenerali analysisofpdl1andcd3expressioninglioblastomapatientsandcorrelationwithoutcomeasinglecenterreport |